D
Dashyant Dhanak
Researcher at Janssen Pharmaceutica
Publications - 61
Citations - 8459
Dashyant Dhanak is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: PRC2 & Urotensin-II receptor. The author has an hindex of 35, co-authored 61 publications receiving 7390 citations. Previous affiliations of Dashyant Dhanak include Radboud University Nijmegen & GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T. McCabe,Heidi M. Ott,Gopinath Ganji,Susan Korenchuk,Christine Thompson,Glenn S. Van Aller,Yan Liu,Alan P. Graves,Anthony Della Pietra,Elsie Diaz,Louis V. LaFrance,Mellinger Mark,Celine Duquenne,Xinrong Tian,Ryan G. Kruger,Charles F. McHugh,Martin Brandt,William H. Miller,Dashyant Dhanak,Sharad K. Verma,Peter J. Tummino,Caretha L. Creasy +21 more
TL;DR: GSK126, a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity, decreases global H3K27me3 levels and reactivates silenced PRC2 target genes and markedly inhibits the growth of EzH2 mutant DLBCL xenografts in mice are demonstrated.
Journal ArticleDOI
ATP citrate lyase inhibition can suppress tumor cell growth
Georgia Hatzivassiliou,Fangping Zhao,Daniel E. Bauer,Charalambos Andreadis,Shaw Antony N,Dashyant Dhanak,Sunil R. Hingorani,David A. Tuveson,Craig B. Thompson +8 more
TL;DR: ACL inhibition by RNAi or the chemical inhibitor SB-204990 limits in vitro proliferation and survival of tumor cells displaying aerobic glycolysis, and these treatments also reduce in vivo tumor growth and induce differentiation.
Journal ArticleDOI
Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Matthew R. Janes,Jingchuan Zhang,Lian-Sheng Li,Rasmus Hansen,Ulf Peters,Xin Guo,Yuching Chen,Anjali Babbar,Sarah J. Firdaus,Levan Darjania,Jun Feng,Jeffrey H. Chen,Shuangwei Li,Shisheng Li,Yun O. Long,Carol Thach,Yuan Liu,Ata Zarieh,Tess Ely,Jeff Kucharski,Linda Kessler,Tao Wu,Ke Yu,Yi Wang,Yvonne Yao,Xiaohu Deng,Patrick P. Zarrinkar,Dirk Brehmer,Dashyant Dhanak,Matthew V. Lorenzi,Dana D. Hu-Lowe,Matthew P. Patricelli,Pingda Ren,Yi Liu +33 more
TL;DR: This study provides in vivo evidence that mutant KRAS can be selectively targeted and reveals ARS-1620 as representing a new generation of KRASG12C-specific inhibitors with promising therapeutic potential.
Journal ArticleDOI
The promise and peril of chemical probes.
Cheryl H. Arrowsmith,James E. Audia,Christopher M. Austin,Jonathan B. Baell,Jonathan Bennett,Julian Blagg,C. Bountra,Paul Brennan,Peter Brown,Mark E. Bunnage,Carolyn Buser-Doepner,Robert M. Campbell,Adrian Carter,Philip Cohen,Robert A. Copeland,Ben Cravatt,Jayme L. Dahlin,Dashyant Dhanak,Aled M. Edwards,Mathias Frederiksen,Stephen V. Frye,Nathanael S. Gray,Charles E. Grimshaw,David Hepworth,Trevor Howe,Kilian Huber,Jian Jin,Stefan Knapp,Joanne Kotz,Ryan G. Kruger,Derek B. Lowe,Mary M. Mader,Brian D. Marsden,Anke Mueller-Fahrnow,Susanne Müller,Ronan C. O'Hagan,John P. Overington,Dafydd R. Owen,Saul H Rosenberg,Bryan L. Roth,Ruth A. Ross,Matthieu Schapira,Stuart L. Schreiber,Brian K. Shoichet,Michael Sundström,Giulio Superti-Furga,Jack Taunton,Leticia Toledo-Sherman,Chris Walpole,Michael A. Walters,Timothy M. Willson,Paul Workman,Robert N. Young,William J. Zuercher +53 more
TL;DR: A community-driven wiki resource to improve quality and convey current best practice on chemical probes, and to help address shortcomings of poor quality or that are used incorrectly generate misleading results.
Journal ArticleDOI
Chromatin proteins and modifications as drug targets
Kristian Helin,Dashyant Dhanak +1 more
TL;DR: A generation of new classes of potent and specific inhibitors for several chromatin-associated proteins have shown promise in preclinical trials, and although the biology of epigenetic regulation is complex, new inhibitors such as these will hopefully be of clinical use in the coming years.